Management of a 14-Year-Old with COVID-19 Symptoms
For a 14-year-old with COVID-19 symptoms, provide supportive care with acetaminophen or ibuprofen for fever/discomfort, monitor for warning signs of severe disease, and reserve specific therapies only for those requiring supplemental oxygen or meeting criteria for multisystem inflammatory syndrome in children (MIS-C).
Initial Assessment and Risk Stratification
Immediately assess for high-risk features that predict severe disease 1:
- Age under 1 year (though not applicable here)
- Obesity or overweight status (RR = 3.21) 2
- Uncontrolled asthma (RR = 13.2) 2
- Immunocompromising conditions
- Oxygen saturation <95% 2
Check vital signs focusing on:
- Respiratory rate and work of breathing
- Oxygen saturation
- Signs of respiratory distress or shock
- Temperature
Diagnostic Testing
Confirm diagnosis with reverse transcription PCR from nasopharyngeal swab as the gold standard 3. Rapid antigen tests are acceptable alternatives 3.
Imaging is NOT routinely needed for mild-moderate symptoms 4. Reserve chest radiography only for moderate-to-severe respiratory symptoms 4.
Treatment Algorithm by Severity
Mild Disease (No Oxygen Requirement)
Outpatient management with symptomatic treatment:
- Acetaminophen or ibuprofen for fever and discomfort 4
- Hydration and rest
- Monitor at home for progression
No antiviral therapy indicated for mild disease 5, 6.
Moderate-Severe Disease (Requiring Oxygen)
Corticosteroids are first-line therapy 5, 6:
- Systemic glucocorticoids recommended for children requiring supplemental oxygen
- This represents the strongest evidence-based recommendation from multiple guidelines
Remdesivir should NOT be routinely administered 6. The evidence shows conflicting recommendations across guidelines, with the most recent high-quality Australian guideline explicitly recommending against routine use 6.
Tocilizumab could be considered in select cases, though evidence is limited and recommendations vary 6. The NHMRC guideline suggests considering it for those requiring oxygen with evidence of systemic inflammation 7.
Respiratory Support Escalation
For hypoxemia unresponsive to low-flow oxygen:
- Consider high-flow nasal cannula or non-invasive ventilation 5, 6
- Ensure appropriate infection control measures are in place
- This should occur in a hospital setting with pediatric critical care capabilities
MIS-C Recognition and Management
Watch for MIS-C (typically presents 2-6 weeks post-infection) with:
- Persistent fever
- Multisystem involvement (cardiac, GI, dermatologic, hematologic)
- Elevated inflammatory markers
- Kawasaki disease-like features
If MIS-C is suspected:
- Immediate multidisciplinary team involvement 6
- IVIG plus methylprednisolone is recommended 7, 5, 6
- Add aspirin and thromboprophylaxis 6
- Transfer to facility with pediatric cardiology and intensive care
Critical Pitfalls to Avoid
- Do not use antibiotics routinely unless bacterial coinfection is suspected
- Do not give remdesivir outside of severe hospitalized cases - evidence does not support routine use in children 6
- Do not miss MIS-C - maintain high suspicion for weeks after acute infection
- Do not delay corticosteroids in children requiring oxygen - this is the only therapy with clear benefit 5, 6
Vaccination Counseling
Ensure vaccination is up to date - vaccines have proven effective in reducing severe disease and post-COVID conditions in adolescents 3.
Follow-Up Considerations
Monitor for post-COVID conditions, though these are rare in children 3. Arrange follow-up if symptoms persist beyond 4 weeks or if there are concerns about cardiac, respiratory, or neuropsychiatric sequelae.